A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132) Meeting Abstract


Authors: Spigel, D.; Spira, A.; Zamarin, D.; McDermott, D. F.; Luke, J.; Heymach, J. V.; Previs, R.; Sullivan, R.; Gandhi, L.; Azrilevich, A.; Rizvi, N.; Oft, M.; Busby, N.; Izar, B.
Abstract Title: A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)
Meeting Title: 113th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title: Cancer Research
Volume: 82
Issue: 12 Suppl.
Meeting Dates: 2022 Apr 8-13
Meeting Location: New Orleans, LA
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2022-06-15
Language: English
ACCESSION: WOS:000892509502183
PROVIDER: wos
DOI: 10.1158/1538-7445.AM2022-CT244
Notes: Meeting Abstract: CT244 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Dmitriy Zamarin
    201 Zamarin